Nancy Lurker was appointed the Company's President & Chief Executive Officer in September 2016. Ms. Lurker has had broad ranging experience in the pharmaceutical industry and companies serving the pharmaceutical industry, including diverse senior leadership positions. From 2008 to 2015, Ms. Lurker served as President and Chief Executive Officer and a Director of PDI, Inc., a NASDAQ-listed healthcare commercialization company. She successfully rebuilt PDI's contract sales business, launching numerous pharmaceutical products for multiple companies across diverse therapeutic areas, including ophthalmology, in advance of a sale of that business line to Publicis Healthcare Communications Group and then repositioned the company as the higher growth, higher margin molecular diagnostics business now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, where she oversaw a multi-billion-dollar product portfolio covering cardiovascular, bone, pain, urology, respiratory, dermatology, biologics, neurology and metabolic therapeutic areas. From 2003 to 2006, she served as President and Chief Executive Officer of Impact Rx, Inc., a privately held healthcare information company, now part of IMS Health Holdings, Inc., where she substantially grew revenues and profitability. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation, where she led a global business unit that commercialized urology, cardiovascular, central nervous system, respiratory and women's health drugs, overseeing the worldwide launch of Detrol and Detrol LA and repositioning Ambien for revenue growth. She also served as a member of Pharmacia's U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker previously served as a member of the Board of Directors of Mallinckrodt Pharmaceuticals,plc (NYSE: MNK) and Auxilium Pharmaceuticals,Inc. (NASDAQ: ENDP). Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.
Leonard Blum currently serves as EyePoint’s Executive Vice President and General Manager, U.S. Mr. Blum brings to EyePoint more than 30 years of successful executive and management experience, most recently serving as Chief Business and Commercial Officer of Omeros Corporation, where he oversaw sales and marketing efforts for OMIDRIA®, a product used by ophthalmologists in conjunction with cataract surgery and intraocular lens replacement to maintain pupil size and reduce postoperative pain. Prior to joining Omeros in 2016, he served as Senior Vice President, Chief Commercial Officer at Theravance, Inc., a publicly traded biopharmaceutical company, and its spin-off company, Theravance BioPharma, from 2007 until 2016. In this capacity, he collaborated with Astellas Pharma in the launch of VIBATIV®, a drug for the treatment of hospital-acquired bacterial pneumonia and complicated skin and soft structure infections, and with Glaxo SmithKline in the launches of BREO® and ANORO®, two combination therapies for the treatment of chronic obstructive pulmonary disease and asthma. Prior to that, Mr. Blum founded and led the commercial functions at ICOS Corporation, a biotechnology company, progressing from Vice President, Marketing to Senior Vice President, Sales and Marketing, from 2000 until the company's acquisition by Eli Lilly and Company in 2007. At ICOS, he was responsible for the launch and commercialization of CIALIS®, which is the worldwide top selling treatment for erectile dysfunction.
Mr. Blum began his career in the pharmaceutical industry at Merck & Co., where he spent thirteen years in positions of increasing responsibility in marketing and business unit leadership in the U.S. and Europe. Over these years, Mr. Blum was responsible for more than a dozen product launches in several therapeutic categories and markets.
Mr. Blum earned his A.B. in Economics, magna cum laude, at Princeton University, studied International Finance on a Fulbright Fellowship at the University of Zurich and completed an M.B.A. at Stanford University's Graduate School of Business. Before entering the pharmaceutical industry, Mr. Blum served as an officer in the U.S. Army Special Forces, and completed his military service at the rank of Captain.
Mr. Nazzaro has served as the Company's Vice President of Operations since November 2009 having previously served as Director of Operations from May 2006 to November 2009. Mr. Nazzaro is the former Director of Manufacturing for Control Delivery Systems. Prior to CDS, Mr. Nazzaro held a variety of positions with Boston Scientific Corporation including responsibilities in logistics, R&D, manufacturing and distribution, including responsibility for distribution of cardiac care devices. Mr. Nazzaro has over 20 years of product life cycle and operations experience. Mr. Nazzaro received a Bachelor of Science degree in Accounting from Suffolk University in Boston, MA.
Dr. Paggiarino joined EyePoint Pharmaceuticals from Lpath, a leader in lipid-targeted therapeutics, where he served as senior vice president and chief development officer. Prior to joining Lpath, he was vice president and therapeutic unit head for retina diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical development pipeline through regulatory approvals worldwide. Dr. Paggiarino previously served as executive director of clinical development and medical affairs at Pfizer Global R&D, with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career he held research and development positions at Angelini Pharmaceuticals, a private company, where he advanced to president of the firm, and Pharmacia Global R&D, where he was clinical program director of ophthalmology with responsibilities including Xalatan®, one of the leading glaucoma therapies in the world. Dr. Paggiarino earned his degree in Medicine and General Surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.
Mr. Ross has served as the Company's Vice President of Finance since November 2009 and was previously Corporate Controller from October 2006. Mr. Ross was designated as the Company's Principal Financial and Accounting Officer in March 2009. Mr. Ross is the former Corporate Controller of NMT Medical, Inc. and previously served as Vice President of Finance and Vice President of International Operations for JetForm Corporation. Mr. Ross brings 30 years of accounting and financial management experience to the Company. Mr. Ross received a Bachelor of Science degree in Chemical Engineering from Tufts University and an MBA from the Amos Tuck School at Dartmouth College.
Dr. Riedel joined EyePoint Pharmaceuticals in October 2011, bringing with him over 29 years of biopharmaceutical R&D experience. Dr. Riedel has contributed significantly to the achievement of regulatory approval of several novel product candidates, including: INFUSE® (dibotermin alfa); Plenaxis® (abarelix), and the first generic version of Lovenox® (enoxaparin sodium). Dr. Riedel has previously served as Vice President, Regulatory Affairs and Program Management at NormOxys, Inc., as Vice President of Regulatory Affairs at Momenta Pharmaceuticals and as Senior Vice President of Regulatory Affairs, Quality Assurance and Project Management at PRAECIS Pharmaceuticals, Inc. Before joining PRAECIS, Dr. Riedel held various senior R&D positions at Wyeth Research and Genetics Institute, Inc. Dr. Riedel received a B.A. degree in Biochemical Sciences from Harvard College and a Ph.D. in Biology from Harvard University.
Dr. Guo has served as the Company's Vice President of Research since November 2009 having previously served as Director of Research from January 2006 to November 2009. Prior to joining EyePoint Pharmaceuticals, Dr. Guo served as the Director of Preformulation and as a Senior Scientist for Control Delivery Systems where she was one of the original inventors of Durasert sustained release drug delivery system. Prior to joining CDS, Dr. Guo was a Post-Doctoral Research Scientist at New England Eye Center and at the University of Kentucky. Dr. Guo received Masters of Science in Medicinal Chemistry and a Bachelor of Science degree in Pharmacy from China Pharmaceutical University and Ph.D. in Medicinal Chemistry from the University of Heidelberg.